Literature DB >> 20396546

Oxaliplatin: is it a new standard weapon for colorectal cancer?

Si-Young Kim.   

Abstract

Entities:  

Year:  2004        PMID： 20396546      PMCID： PMC2855101          DOI： 10.4143/crt.2004.36.2.91

Source DB:  PubMed          Journal:  Cancer Res Treat        ISSN： 1598-2998            Impact factor:   4.679


× No keyword cloud information.
  10 in total

1.  Randomised trial comparing three different schedules of infusional 5FU and raltitrexed alone as first-line therapy in metastatic colorectal cancer. Final results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 trial.

Authors:  M Ducreux; O Bouche; J P Pignon; M Mousseau; J L Raoul; P Cassan; B Leduc; C Berger; A Dunant; J Fournet; L Bedenne
Journal:  Oncology       Date:  2006-06-30       Impact factor: 2.935

2.  Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.

Authors:  J Y Douillard; D Cunningham; A D Roth; M Navarro; R D James; P Karasek; P Jandik; T Iveson; J Carmichael; M Alakl; G Gruia; L Awad; P Rougier
Journal:  Lancet       Date:  2000-03-25       Impact factor: 79.321

3.  Oxaliplatin with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (Modified FOLFOX 4) as first-line therapy for patients with metastatic colorectal cancer.

Authors:  Hyuk-Chan Kwon; Kyoung Tae Kim; Shin Ae Lee; Jong-Sung Park; Sung-Hyun Kim; Jae-Seok Kim; Hyo Jin Kim
Journal:  Cancer Res Treat       Date:  2004-04-30       Impact factor: 4.679

4.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

Authors:  L B Saltz; J V Cox; C Blanke; L S Rosen; L Fehrenbacher; M J Moore; J A Maroun; S P Ackland; P K Locker; N Pirotta; G L Elfring; L L Miller
Journal:  N Engl J Med       Date:  2000-09-28       Impact factor: 91.245

5.  Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.

Authors:  P Piedbois; P Rougier; M Buyse; J Pignon; L Ryan; R Hansen; B Zee; B Weinerman; J Pater; C Leichman; J Macdonald; J Benedetti; J Lokich; J Fryer; G Brufman; R Isacson; A Laplanche; E Levy
Journal:  J Clin Oncol       Date:  1998-01       Impact factor: 44.544

6.  Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines.

Authors:  D Machover; E Diaz-Rubio; A de Gramont; A Schilf; J J Gastiaburu; S Brienza; M Itzhaki; G Metzger; D N'Daw; J Vignoud; A Abad; E Francois; E Gamelin; M Marty; J Sastre; J F Seitz; M Ychou
Journal:  Ann Oncol       Date:  1996-01       Impact factor: 32.976

7.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

Authors:  A de Gramont; A Figer; M Seymour; M Homerin; A Hmissi; J Cassidy; C Boni; H Cortes-Funes; A Cervantes; G Freyer; D Papamichael; N Le Bail; C Louvet; D Hendler; F de Braud; C Wilson; F Morvan; A Bonetti
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

8.  A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

Authors:  Richard M Goldberg; Daniel J Sargent; Roscoe F Morton; Charles S Fuchs; Ramesh K Ramanathan; Stephen K Williamson; Brian P Findlay; Henry C Pitot; Steven R Alberts
Journal:  J Clin Oncol       Date:  2003-12-09       Impact factor: 44.544

Review 9.  Oxaliplatin: a review of preclinical and clinical studies.

Authors:  E Raymond; S G Chaney; A Taamma; E Cvitkovic
Journal:  Ann Oncol       Date:  1998-10       Impact factor: 32.976

10.  Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project.

Authors: 
Journal:  J Clin Oncol       Date:  1992-06       Impact factor: 44.544
  10 in total
  1 in total

1.  Combination chemotherapy of oxaliplatin, 5-fluorouracil and low dose leucovorin in patients with advanced colorectal cancer.

Authors:  Yoon Mi Shin; Hae Suk Han; Seong Woo Lim; Byung Chul Kim; Kyung Suck Cheoi; Young Ook Eum; Seung Taek Kim; Ki Hyeong Lee
Journal:  Cancer Res Treat       Date:  2005-10-31       Impact factor: 4.679
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.